NCT05638451 2024-06-05
Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
Zhujiang Hospital
Phase 2 Unknown
Clinical Trials
41 trialsNCT03951142 2023-11-01
ImPRESS
Oslo University Hospital
Phase 2 Unknown
NCT04671459 2023-06-28
TaRRGET
Prof. Franciszek Lukaszczyk Memorial Oncology Center
Phase 2 Unknown
NCT05191784 2023-06-12
GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
Genexine, Inc.
Phase 2 Unknown
NCT04223999 2023-06-06
OptimalTTF-2
University of Aarhus
Phase 2 Unknown
NCT02137759 2023-05-06
MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
Emory University
Phase 2 Unknown
NCT04888611 2021-11-30
Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma
Huashan Hospital
Phase 2 Unknown
NCT04874506 2021-05-05
MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)
Matrix Biomed, Inc.
Phase 2 Unknown
NCT04715620 2021-01-20
Niraparib Combined With Radiotherapy in rGBM
Tianjin Huanhu Hospital
Phase 2 Unknown
NCT04674527 2020-12-19
Pilot Study of Elemene in Treating Patients With Refractory Glioblastoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04583020 2020-11-30
Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04552977 2020-09-17
A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT04547855 2020-09-14
Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen
Sun Yat-sen University
Phase 2 Unknown
NCT01567202 2020-09-09
Study of DC Vaccination Against Glioblastoma
Huashan Hospital
Phase 2 Unknown
NCT02715297 2020-03-10
GlioCave/NOA17
Technical University of Munich
Phase 2 Unknown
NCT00276783 2020-03-05
Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases
Northwestern University
Phase 2 Unknown
NCT04224441 2020-01-13
RACTAC
Regina Elena Cancer Institute
Phase 2 Unknown
NCT04157478 2019-11-12
Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma
People's Hospital of Guangxi Zhuang Autonomous Region
Phase 2 Unknown
NCT03916757 2019-04-17
GBM
Immunitor LLC
Phase 2 Unknown
NCT02945826 2018-04-10
uPAR-PET/MRI in Glioblastoma Multiforme
Rigshospitalet, Denmark
Phase 2 Unknown
NCT03212235 2017-07-11
Hypofractionated Radiation Therapy for Glioblastoma
Instituto do Cancer do Estado de São Paulo
Phase 2 Unknown
NCT02928575 2016-10-10
Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Unknown
NCT02815410 2016-06-28
Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients
Seoul National University Hospital
Phase 2 Unknown
NCT02772094 2016-05-13
Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas)
China Medical University Hospital
Phase 2 Unknown
NCT02663440 2016-01-26
Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT01124539 2014-12-09
Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma
Arno Therapeutics
Phase 2 Unknown
NCT01403311 2014-03-26
ALA
Legacy Health System
Phase 2 Unknown
NCT00054496 2014-01-10
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00492687 2014-01-10
Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00006656 2013-11-06
Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01737346 2012-12-03
Procarbazine and Lomustine in Recurrent Glioblastoma
Incheon St.Mary's Hospital
Phase 2 Unknown
NCT01124240 2011-07-26
ExCentric
Northern Sydney and Central Coast Area Health Service
Phase 2 Unknown
NCT01252459 2010-12-16
GLIAA
University Hospital Freiburg
Phase 2 Unknown
NCT00562419 2010-10-27
CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
Adnexus, A Bristol-Myers Squibb R&D Company
Phase 2 Unknown
NCT00535379 2010-08-30
SURGE01-07
Medical University Innsbruck
Phase 2 Unknown
NCT00643825 2010-07-23
PATSGO
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Unknown
NCT00936052 2010-07-16
HBO
Neurological Surgery, P.C.
Phase 2 Unknown
NCT01083719 2010-03-10
A Comparison of FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.
Medanta Institute of Clinical Research
Phase 2 Unknown
NCT00906516 2009-05-21
Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme
Bradmer Pharmaceuticals Inc.
Phase 2 Unknown
NCT00114309 2009-04-03
131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
TransMolecular
Phase 2 Unknown
NCT00521482 2007-08-28
Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma
University of Zurich
Phase 2 Unknown